Simon D S Fraser1, Paul J Roderick2, Natasha J McIntyre3, Scott Harris2, Christopher W McIntyre4, Richard J Fluck3, Maarten W Taal3. 1. Academic Unit of Primary Care and Population Sciences, Southampton General Hospital, Southampton, Hampshire, United Kingdom; s.fraser@soton.ac.uk. 2. Academic Unit of Primary Care and Population Sciences, Southampton General Hospital, Southampton, Hampshire, United Kingdom; 3. Department of Renal Medicine, Royal Derby Hospital National Health Service Foundation Trust, Derby, Derbyshire, United Kingdom; and. 4. Department of Nephrology, Division of Medical Sciences and Graduate-Entry Medicine, University of Nottingham, Nottingham, United Kingdom.
Abstract
BACKGROUND AND OBJECTIVES: Novel markers may help to improve risk prediction in CKD. One potential candidate is tissue advanced glycation end product accumulation, a marker of cumulative metabolic stress, which can be assessed by a simple noninvasive measurement of skin autofluorescence. Skin autofluorescence correlates with higher risk of cardiovascular events and mortality in people with diabetes or people requiring RRT, but its role in earlier CKD has not been studied. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: A prospective cohort of 1741 people with CKD stage 3 was recruited from primary care between August 2008 and March 2010. Participants underwent medical history, clinical assessment, blood and urine sampling for biochemistry, and measurement of skin autofluorescence. Kaplan-Meier plots and multivariate Cox proportional hazards models were used to investigate associations between skin autofluorescence (categorical in quartiles) and all-cause mortality. RESULTS: In total, 1707 participants had skin autofluorescence measured; 170 (10%) participants died after a median of 3.6 years of follow-up. The most common cause of death was cardiovascular disease (41%). Higher skin autofluorescence was associated significantly with poorer survival (all-cause mortality, P<0.001) on Kaplan-Meier analysis. Univariate and age/sex-adjusted Cox proportional hazards models showed that the highest quartile of skin autofluorescence was associated with all-cause mortality (hazard ratio, 2.64; 95% confidence interval, 1.71 to 4.08; P<0.001 and hazard ratio, 1.84; 95% confidence interval, 1.18 to 2.86; P=0.003, respectively, compared with the lowest quartile). This association was not maintained after additional adjustment to include cardiovascular disease, diabetes, smoking, body mass index, eGFR, albuminuria, and hemoglobin. CONCLUSIONS: Skin autofluorescence was not independently associated with all-cause mortality in this study. Additional research is needed to clarify whether it has a role in risk prediction in CKD.
BACKGROUND AND OBJECTIVES: Novel markers may help to improve risk prediction in CKD. One potential candidate is tissue advanced glycation end product accumulation, a marker of cumulative metabolic stress, which can be assessed by a simple noninvasive measurement of skin autofluorescence. Skin autofluorescence correlates with higher risk of cardiovascular events and mortality in people with diabetes or people requiring RRT, but its role in earlier CKD has not been studied. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: A prospective cohort of 1741 people with CKD stage 3 was recruited from primary care between August 2008 and March 2010. Participants underwent medical history, clinical assessment, blood and urine sampling for biochemistry, and measurement of skin autofluorescence. Kaplan-Meier plots and multivariate Cox proportional hazards models were used to investigate associations between skin autofluorescence (categorical in quartiles) and all-cause mortality. RESULTS: In total, 1707 participants had skin autofluorescence measured; 170 (10%) participants died after a median of 3.6 years of follow-up. The most common cause of death was cardiovascular disease (41%). Higher skin autofluorescence was associated significantly with poorer survival (all-cause mortality, P<0.001) on Kaplan-Meier analysis. Univariate and age/sex-adjusted Cox proportional hazards models showed that the highest quartile of skin autofluorescence was associated with all-cause mortality (hazard ratio, 2.64; 95% confidence interval, 1.71 to 4.08; P<0.001 and hazard ratio, 1.84; 95% confidence interval, 1.18 to 2.86; P=0.003, respectively, compared with the lowest quartile). This association was not maintained after additional adjustment to include cardiovascular disease, diabetes, smoking, body mass index, eGFR, albuminuria, and hemoglobin. CONCLUSIONS: Skin autofluorescence was not independently associated with all-cause mortality in this study. Additional research is needed to clarify whether it has a role in risk prediction in CKD.
Authors: S D Yan; H Zhu; A Zhu; A Golabek; H Du; A Roher; J Yu; C Soto; A M Schmidt; D Stern; M Kindy Journal: Nat Med Date: 2000-06 Impact factor: 53.440
Authors: A Taguchi; D C Blood; G del Toro; A Canet; D C Lee; W Qu; N Tanji; Y Lu; E Lalla; C Fu; M A Hofmann; T Kislinger; M Ingram; A Lu; H Tanaka; O Hori; S Ogawa; D M Stern; A M Schmidt Journal: Nature Date: 2000-05-18 Impact factor: 49.962
Authors: T Miyata; Y Wada; Z Cai; Y Iida; K Horie; Y Yasuda; K Maeda; K Kurokawa; C van Ypersele de Strihou Journal: Kidney Int Date: 1997-04 Impact factor: 10.612
Authors: Jasper W L Hartog; Yoran M Hummel; Adriaan A Voors; Casper G Schalkwijk; Toshio Miyata; Roel M Huisman; Andries J Smit; Dirk J Van Veldhuisen Journal: J Card Fail Date: 2008-05-27 Impact factor: 5.712
Authors: Andréa E M Stinghen; Ziad A Massy; Helen Vlassara; Gary E Striker; Agnès Boullier Journal: J Am Soc Nephrol Date: 2015-08-26 Impact factor: 10.121
Authors: C Blanc-Bisson; F L Velayoudom-Cephise; A Cougnard-Gregoire; C Helmer; K Rajaobelina; C Delcourt; L Alexandre; L Blanco; K Mohammedi; M Monlun; V Rigalleau Journal: Cardiovasc Diabetol Date: 2018-06-08 Impact factor: 9.951
Authors: Robert P van Waateringe; Bernardina T Fokkens; Sandra N Slagter; Melanie M van der Klauw; Jana V van Vliet-Ostaptchouk; Reindert Graaff; Andrew D Paterson; Andries J Smit; Helen L Lutgers; Bruce H R Wolffenbuttel Journal: Diabetologia Date: 2018-11-21 Impact factor: 10.122
Authors: Henderikus E Boersma; Robert P van Waateringe; Melanie M van der Klauw; Reindert Graaff; Andrew D Paterson; Andries J Smit; Bruce H R Wolffenbuttel Journal: BMC Endocr Disord Date: 2021-01-12 Impact factor: 2.763
Authors: Ninon Foussard; Alice Larroumet; Marine Rigo; Kamel Mohammedi; Laurence Baillet-Blanco; Pauline Poupon; Marie Monlun; Maxime Lecocq; Anne-Claire Devouge; Claire Ducos; Marion Liebart; Quentin Battaglini; Vincent Rigalleau Journal: BMJ Open Diabetes Res Care Date: 2021-03
Authors: Ivan Cavero-Redondo; Alba Soriano-Cano; Celia Álvarez-Bueno; Pedro G Cunha; Jose A Martínez-Hortelano; Miriam Garrido-Miguel; Carlos Berlanga-Macías; Vicente Martínez-Vizcaíno Journal: J Am Heart Assoc Date: 2018-09-18 Impact factor: 5.501